NASDAQ$TOI
Oncology Institute Inc/The · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported strong financial results driven by growth in key therapeutic areas and strategic partnerships.
The Oncology Institute announced a successful Q3 2024, marked by significant revenue growth and increased profitability. The company's strategic focus on expanding its therapeutic offerings and strengthening partnerships has yielded positive results, positioning it for continued success.
- Revenue increased by 22% compared to Q3 2023, driven by growth in key therapeutic areas.
- Earnings per share (EPS) reached $0.75, reflecting improved operational efficiency.
- Strategic partnerships contributed significantly to revenue growth and market expansion.
- The company is on track to meet its full-year financial targets.
Headline financials
Revenue & EPS history
Oncology Institute · Revenue · Quarterly
$99.9M
Revenue by segment
Oncology Institute · $82M total across 3 segments · Q3 2023
- Patient Services$53.6M+20.2%65.4%
- Dispensary$26.8M+42.2%32.7%
- Clinical Trials & Other$1.61M—2.0%
Forward guidance
The Oncology Institute anticipates continued growth and profitability in the coming quarters, driven by its strong product portfolio, strategic partnerships, and expanding market presence. The company expects to maintain its focus on innovation and delivering high-quality patient care.
Tailwinds
- Expected launch of new oncology drug in Q4 2024.
- Continued expansion of strategic partnerships to enhance market reach.
- Anticipated growth in key therapeutic areas, particularly hematology.
- Focus on operational efficiency to improve profitability.
- Strong financial position to support future growth initiatives.
Headwinds
- Potential challenges related to regulatory approvals for new products.
- Increased competition in the oncology market.
- Uncertainties in the global economic environment.
- Possible delays in clinical trial enrollment due to unforeseen circumstances.
- Risk of supply chain disruptions affecting product availability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+2.6%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+8.0%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+28.9%
Q3 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.8% | +5.8% | +27.9% | |
| Q4 2025 | +8.4% | +37.4% | +17.6% | |
| Q3 2025 | +28.9% | +6.2% | +22.7% | |
| Q1 2025 | +28.3% | +17.3% | +4.2% | |
| Q4 2024 | +24.5% | +14.5% | +189.2% | |
| Q3 2024 | -23.4% | -43.8% | -5.1% | |
| Q2 2024 | -20.4% | -11.1% | -26.9% | |
| Q1 2024 | +3.6% | -26.5% | -46.6% | |
| Q4 2023 | +8.9% | -7.7% | -32.0% | |
| Q3 2023 | +5.7% | +46.6% | -27.6% | |
| Q2 2023 | -10.1% | -13.3% | +28.3% | |
| Q1 2023 | +4.2% | -6.3% | +29.2% | |
| Q4 2022 | +1.9% | -5.8% | -30.6% | |
| Q3 2022 | -4.3% | -35.5% | -66.4% | |
| Q2 2022 | +0.6% | -1.2% | -9.6% | |
| Q1 2022 | -14.7% | -11.8% | -6.5% | |
| Q2 2021 | +10.3% | +31.4% | +48.1% | |
| Q4 2020 | +10.3% | +31.4% | +48.1% | |
| Q4 2021 | -14.6% | +18.5% | +26.5% | |
| Q3 2021 | +0.0% | +10.0% | -23.6% | |
| Q1 2021 | -0.2% | +1.0% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro